MX2010004259A - Tratamientos antitumorales mejorados. - Google Patents

Tratamientos antitumorales mejorados.

Info

Publication number
MX2010004259A
MX2010004259A MX2010004259A MX2010004259A MX2010004259A MX 2010004259 A MX2010004259 A MX 2010004259A MX 2010004259 A MX2010004259 A MX 2010004259A MX 2010004259 A MX2010004259 A MX 2010004259A MX 2010004259 A MX2010004259 A MX 2010004259A
Authority
MX
Mexico
Prior art keywords
improved antitumoral
antitumoral treatments
treatments
improved
combinations
Prior art date
Application number
MX2010004259A
Other languages
English (en)
Spanish (es)
Inventor
Roman Perez-Soler
Yi-He Ling
Jose Maria Jimeno Donaque
Yi-Yu Zou
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2010004259A publication Critical patent/MX2010004259A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2010004259A 2007-10-19 2008-10-17 Tratamientos antitumorales mejorados. MX2010004259A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98143107P 2007-10-19 2007-10-19
PCT/US2008/080309 WO2009052379A2 (en) 2007-10-19 2008-10-17 Improved antitumoral treatments

Publications (1)

Publication Number Publication Date
MX2010004259A true MX2010004259A (es) 2010-08-31

Family

ID=40568081

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004259A MX2010004259A (es) 2007-10-19 2008-10-17 Tratamientos antitumorales mejorados.

Country Status (12)

Country Link
US (1) US20100226919A1 (enExample)
EP (1) EP2207561A2 (enExample)
JP (1) JP2011500723A (enExample)
KR (1) KR20100099128A (enExample)
CN (1) CN101861159A (enExample)
AU (1) AU2008312400A1 (enExample)
CA (1) CA2703720A1 (enExample)
IL (1) IL205096A0 (enExample)
MX (1) MX2010004259A (enExample)
NZ (1) NZ584695A (enExample)
RU (1) RU2010119922A (enExample)
WO (1) WO2009052379A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2252315A1 (en) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
JP2011513370A (ja) * 2008-03-07 2011-04-28 ファルマ・マール・ソシエダード・アノニマ 改善された抗腫瘍治療法
WO2012103341A1 (en) * 2011-01-27 2012-08-02 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid stage tumors using anti-erbb3 antibodies
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
MX2022008874A (es) * 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
ATE247168T1 (de) * 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1998002434A1 (en) * 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
WO1998050406A1 (en) * 1997-05-09 1998-11-12 The General Hospital Corporation Cell proliferation related genes
JP3948501B2 (ja) * 1997-08-07 2007-07-25 Ｎｓｋワーナー株式会社 ブレーキドラム
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
EP1131304B1 (en) * 1998-11-19 2002-12-04 Warner-Lambert Company N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
AU2002210749B2 (en) * 2000-10-31 2006-12-21 Pharma Mar, S.A. Kahalalide F formulation
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
MXPA05004133A (es) * 2002-10-18 2005-10-05 Pharma Mar Sau Nuevos compuestos antitumorales.
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
KR101353706B1 (ko) * 2006-02-03 2014-02-18 유니버시티 오브 워싱톤 전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제

Also Published As

Publication number Publication date
CA2703720A1 (en) 2009-04-23
EP2207561A2 (en) 2010-07-21
JP2011500723A (ja) 2011-01-06
US20100226919A1 (en) 2010-09-09
CN101861159A (zh) 2010-10-13
RU2010119922A (ru) 2011-11-27
WO2009052379A3 (en) 2009-07-23
KR20100099128A (ko) 2010-09-10
IL205096A0 (en) 2010-11-30
NZ584695A (en) 2011-06-30
AU2008312400A1 (en) 2009-04-23
WO2009052379A2 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MY191825A (en) Therapeutic compounds and compositions
WO2010118063A3 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
MX2010006991A (es) Tratamientos de cancer terapeuticos.
MX2011008221A (es) Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
JO3134B1 (ar) مثبطات نشاط akt
MX2010009669A (es) Terapia de combinacion con antagonistas de c-met y egfr.
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
MX2011006150A (es) Compuestos inhibidores de cinasa.
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
IN2012DN02046A (enExample)
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MX2012003851A (es) Tratamiento de cánceres resistentes antagonistas notch1, mediante el uso de antagonistas notch3.
WO2015009726A3 (en) Medical uses of cd38 agonists
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
WO2007129226A3 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
MX377618B (es) Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
IL207310A0 (en) Vaccine compositions
JO2833B1 (en) Amino pyrazole compound
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.